G6 continuous glucose monitor (CGM) receivers deliver glucose readings and alerts. However, certain devices may experience an ...

Dexcom (Nasdaq:DXCM) announced today that it plans to establish a direct presence in Italy, bringing its CGM technology to ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

Second, DexCom has expanded its product offerings. Last year, it launched Stelo in the U.S., an over-the-counter CGM option that can be used by pre-diabetes patients. This initiative significantly ...

Get prepared with the key expectations. DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track glucose levels. The company ...

DexCom (NASDAQ:DXCM) shares popped 6% premarket ... This outlook considers sensor volume growth driven by increasing CGM access and awareness for people with diabetes, the continued rollout ...

SAN FRANCISCO—After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have diabetes, Dexcom said it expects to see more than $4.03 ...

is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the ...